Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

Charles Andy Schuetz,1 Siew Hwa Ong,2 Matthias Blüher3 1Evidera Inc., Bethesda, MD, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Department of Medicine, University of Leipzig, Leipzig, Germany Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic agents...

Full description

Bibliographic Details
Main Authors: Schuetz CA, Ong SH, Blüher M
Format: Article
Language:English
Published: Dove Medical Press 2015-06-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/clinical-trial-simulation-methods-for-estimating-the-impact-of-dpp-4-i-peer-reviewed-article-CEOR

Internet

http://www.dovepress.com/clinical-trial-simulation-methods-for-estimating-the-impact-of-dpp-4-i-peer-reviewed-article-CEOR

Similar Items